Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70934 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Masaru Matsui und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Nara Medical University, Nara, Japan. Hauptthemen laut MEDLINE: Diabetic Nephropathies, Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Naphthyridines. Die Arbeit nennt 36 Literaturangaben.
Abstract (Originalsprache)
Background
Despite treatment with renin–angiotensin system inhibitors (RASis) and sodium–glucose cotransporter 2 inhibitors (SGLT2is), diabetic kidney disease (DKD) continues to exhibit substantial residual renal risk. The renoprotective effects of adding finerenone to dual therapy remain incompletely characterised.
Methods
A total of 255 patients with DKD receiving combined RASi and SGLT2i therapy were analysed by intention‐to‐treat as triple combination therapy (TCT) with finerenone or dual combination therapy (DCT) alone. The outcomes were longitudinal changes in proteinuria, serum potassium and estimated glomerular filtration rate (eGFR) slope, including total eGFR slope over 24 months and the post–initial dip eGFR slope from 3 to 24 months, evaluated before and after propensity score (PS) matching.
Results
Over a 24‐month follow‐up period, TCT was associated with a greater and sustained reduction in proteinuria compared with DCT, with significant reductions of 47% at 24 months ( p = 0.028). Although the total eGFR slope did not differ significantly between groups, the post–initial dip slope was significantly improved in the TCT group, with an attenuation of annual eGFR decline by approximately 1.31 mL/min/1.73 m 2 /year (95% CI: 0.25 to 2.36) compared with DCT ( p = 0.015). After PS matching, this association remained significant (between‐group difference 1.45 mL/min/1.73 m 2 /year; 95% CI: 0.32–2.58; p = 0.012). Serum potassium increased modestly in the early phase of TCT but stabilised thereafter, with no significant difference between groups at 24 months.
Conclusions
Among patients with DKD receiving RASi and SGLT2i therapy, the addition of finerenone was associated with greater proteinuria reduction and a significant improvement in the post–initial dip eGFR slope, suggesting that TCT may offer an additional renoprotective strategy in DKD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nephrology, Nara Medical University, Nara, Japan.
- Department of Nephrology, Nara Prefectural General Medical Center, Nara, Japan.
ORCID-Profile: Masaru Matsui, Masahiro Eriguchi
Zitieren
APA
Matsui, M., Nishimoto, M., Kosugi, T., Kitamura, S., Oda, A., Kawakami, M., Itano, A., Uemura, T., Tamaki, H., Tasaki, H., Okamoto, K., Eriguchi, M., Samejima, K. I., & Tsuruya, K. (2026). Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70934
Vancouver
Matsui M, Nishimoto M, Kosugi T, Kitamura S, Oda A, Kawakami M, et al. Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70934
BibTeX
@article{Matsui2026,
author = {Matsui, Masaru and Nishimoto, Masatoshi and Kosugi, Takaaki and Kitamura, Shunsuke and Oda, Aiko and Kawakami, Masato and Itano, Akiko and Uemura, Takayuki and Tamaki, Hiroyuki and Tasaki, Hikari and Okamoto, Keisuke and Eriguchi, Masahiro and Samejima, Ken-Ichi and Tsuruya, Kazuhiko},
title = {Adding Finerenone to SGLT2 Inhibitors and Long‐Term Kidney Outcomes in Diabetic Kidney Disease},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70934}
}
EUVIMED